5％阿维菌素·噻唑膦复配型微胶囊悬浮剂制备及性能

目的]为了降低阿维菌素和噻唑膦的分解以及对作物的药害,提高其药效,制备阿维菌素·噻唑膦复配型微胶囊悬浮剂。方法]以甲苯二异氰酸酯(TDI)和乙二胺为反应单体,阿维菌素和噻唑膦为芯材,二甲苯为溶剂,采用界面聚合法制备微胶囊。结果]该微胶囊的平均粒径为6.095μm,近似圆球形,表明光滑,阿维菌素和噻唑膦的包封率分别达到99.51%和80.86%,载药量分别为1.03%和4.02%,悬浮率分别为85.43%和97.74%。该微胶囊悬浮剂的缓释性能优于85%噻唑膦原药、20%噻唑膦水乳剂、1.8%阿维菌素乳油和3%阿维菌素水乳剂;该微胶囊悬浮剂具有优异的屏蔽紫外光降解性能。结论]阿维菌素和噻唑膦通过界面聚合法微胶囊化后可以显著增强其缓释和屏蔽紫外光降解性能。

Preparation and Properties of Avermectin and Fosthiazate 5%Complex Microcapsule Suspension

Aims]In order to reduce the decomposition of avermectin and fosthiazate and their phytotoxicity on crops,and to improve their efficacy,avermectin and fosthiazate complex microcapsule suspensions were prepared.Methods]The microcapsules were prepared with toluene diisocyanate and ethylenediamine as monomers,avermectin and fosthiazate as core materials,and xylene as solvent by interfacial polymerization.Results]The average particle size of the microcapsules was 6.095μm.The morphology of the microcapsule was approximately smooth sphere;the encapsulation efficiency of avermectin and fosthiazate were 99.51 and 80.86%,respectively.The durg loadings of avermectin and fosthiazate were 1.03 and 4.02%,respectively.The suspensibility of avermectin and fosthiazate were85.43 and 97.74%respectively.The experimental results showed that the slow release properties of microcapsule suspensions were better than fosthiazate 85%original drugs,fosthiazate 20%EW,avermectin 1.8%EC and avermectin3%EW.In addition,the microcapsule suspension had excellent UV shielding properties.Conclusions]The microencapsulation of avermectin and fosthiazate by interfacial polymerization can significantly enhance the slow release and UV shielding properties.